This study is a randomized, open-label, controlled, group sequential adaptive platform trial, conducted in low-risk patients with Influenza, recruited from outpatient COVID-19/ Acute Respiratory Infection (ARI) clinics or through other approved facilities. Previously healthy patients 18 to 60 years old with early symptomatic Influenza and without co-morbidities are eligible for the study. Enrolled patients are followed up daily for 7 days and then on Day 14. Phone follow-up is conducted on Day 28 and Day 120. This study aims to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity. In this study, we will compare the performance of available influenza antivirals, and those with potential activity, relative to the control (no study drug) and each other. The study currently includes Oseltamivir, Baloxavir, Favipiravir and Molnupiravir in the treatment arms. The key metric to be assessed in this study is the viral clearance rate.